Jagsonpal Pharma

Market Cap: Small Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE048B01035
NSEID: JAGSNPHARM
BSEID: 507789

INR

214.00

12.1 (5.99%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 1.22 lacs

{
  "main_header": {
    "sid": 134241,
    "name": "Jagsonpal Pharma",
    "stock_name": "Jagsonpal Pharma",
    "full_name": "Jagsonpal Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/jagsonpal-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "214.00",
    "chg": 12.1,
    "chgp": "5.99%",
    "dir": 1,
    "prev_price": "201.90",
    "mcapval": "1,420.68 Cr",
    "mcap": "Small Cap",
    "scripcode": 507789,
    "symbol": "JAGSNPHARM",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE048B01035",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "01:24 AM",
    "bse_nse_vol": "1.22 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jagsonpal-pharma-134241-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Jagsonpal Pharmaceuticals Faces Significant Stock Volatility Amid Challenging Market Conditions",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-stock-declines-7-28-amid-ongoing-market-challenges-1271006",
        "imagepath": "",
        "date": "2025-03-11 09:35:05",
        "description": "Jagsonpal Pharmaceuticals, a small-cap player in the Pharmaceuticals & Drugs industry, has experienced significant volatility in its stock performance today. The stock opened with a notable loss of 7.28%, reflecting a challenging market environment. Throughout the day, it reached an intraday low of Rs 200.5, marking a decline of 7.28% from the previous close.\n\nIn terms of performance metrics, Jagsonpal Pharmaceuticals has underperformed its sector by 3.43% today. Over the past two days, the stock has shown a consecutive decline, with a total drop of 6.16%. When compared to the broader market, the stock's one-day performance of -4.28% contrasts with the Sensex's modest decline of 0.53%. Additionally, the stock's one-month performance stands at -6.25%, while the Sensex has decreased by 3.37% during the same period.\n\nAnalyzing moving averages, the stock is currently positioned higher than its 200-day moving av..."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Shows Strong Rebound Amid Market Volatility in February 2025",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-stock-rises-7-61-on-february-12-2025-after-decline-992411",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/JagsonpalPharma_priceRelatedfactors_421717.png",
        "date": "2025-02-12 11:45:15",
        "description": "Jagsonpal Pharmaceuticals experienced notable trading activity on February 12, 2025, rebounding after three days of decline. The stock reached an intraday high of Rs 236, showcasing significant volatility. Over the past month, it has outperformed the Sensex, highlighting its resilience in a challenging market environment."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Faces Significant Intraday Volatility Amid Broader Market Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-declines-7-19-amid-broader-market-downturn-on-february-11-2025-967825",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/JagsonpalPharma_priceRelatedfactors_409563.png",
        "date": "2025-02-11 14:00:15",
        "description": "Jagsonpal Pharmaceuticals has faced notable volatility, with its stock price declining significantly today after an initial gain. The company has underperformed compared to its sector and the broader market over recent days, experiencing consecutive losses. Despite today's downturn, it has shown positive performance over the past month."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Reports 179.14% Net Profit Growth in Q3 FY24-25",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-reports-179-14-net-profit-growth-in-q3-fy24-25-2-924710",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/JagsonpalPharma_mojoScore_397720.png",
        "date": "2025-02-10 18:42:44",
        "description": "Jagsonpal Pharmaceuticals has recently experienced a change in evaluation following a strong financial performance in Q3 FY24-25, highlighted by a 179.14% increase in net profit. The company has shown consistent growth over three quarters, with net sales reaching Rs 148.72 crore, up 41.56%."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Faces Short-Term Challenges Amidst Long-Term Resilience in Market",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-declines-8-97-on-february-10-underperforming-sector-by-3-83-910865",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/JagsonpalPharma_priceRelatedfactors_396897.png",
        "date": "2025-02-10 10:15:13",
        "description": "Jagsonpal Pharmaceuticals has faced a challenging trading day, with its stock price declining significantly and underperforming its sector. Despite recent losses, the company has shown resilience over the past month, outperforming the Sensex. Technical indicators reveal a mixed performance, with the stock above several moving averages but below the 5-day average."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Outperforms Market with Strong Stock Performance and Resilience",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-stock-rises-9-82-outperforming-sector-by-5-67-on-february-6-2025-768400",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/JagsonpalPharma_priceRelatedfactors_382860.png",
        "date": "2025-02-06 15:15:15",
        "description": "Jagsonpal Pharmaceuticals has demonstrated strong market performance, gaining 9.82% on February 6, 2025, significantly outperforming the Sensex. The stock reached an intraday high of Rs 269.75 and has shown a 10.53% increase over the past month, reflecting its competitive position in the pharmaceuticals sector."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Reports 179% Net Profit Growth in Q3 FY24-25 Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-reports-179-14-net-profit-growth-in-q3-fy24-25-746383",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/JagsonpalPharma_mojoScore_352229.png",
        "date": "2025-02-04 18:32:51",
        "description": "Jagsonpal Pharmaceuticals has recently adjusted its evaluation, reflecting strong financial performance in Q3 FY24-25, with a significant increase in net profit and sales. The company maintains a low debt-to-equity ratio and has shown consistent positive results over the past three quarters, despite facing some market challenges."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Shows Resilience Amid Market Fluctuations with Notable Stock Gains",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-stock-rises-7-97-amid-sector-gains-on-january-30-2025-540722",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/1/JagsonpalPharma_priceRelatedfactors_286291.png",
        "date": "2025-01-30 10:15:14",
        "description": "Jagsonpal Pharmaceuticals has demonstrated notable activity, with a significant stock increase on January 30, 2025. The stock has shown a positive trend over the past three days, outperforming the broader market. Despite some intraday volatility, it remains above several key moving averages, indicating resilience in a fluctuating market."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Shows Strong Short-Term Performance Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-stock-rises-8-82-on-january-29-2025-outperforming-sector-380271",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/1/JagsonpalPharma_priceRelatedfactors_279073.png",
        "date": "2025-01-29 14:30:13",
        "description": "Jagsonpal Pharmaceuticals has seen a notable rise in stock performance, gaining 8.82% on January 29, 2025, and outperforming its sector. The stock has shown a consistent upward trend over two days, accumulating an 11.11% return, while facing challenges with a monthly decline amid broader market fluctuations."
      }
    ],
    "total": 68,
    "sid": "134241",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/jagsonpal-pharmaceuticals-134241"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Apr-2025",
      "details": "Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations 2018",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)",
      "datetime": "02-Apr-2025",
      "details": "Further to our disclosure dated December 16 2023 regarding the receipt of Demand cum Show Cause Notice from the Office of the Principal Commissioner of Customs (the Authority) we wish to submit that the Authority has now passed an order as detailed under Annexure-A. The date of occurrence of event/information is the receipt of order from Office of the Principal Commissioner of Customs i.e. on April 2 2025.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Mar-2025",
      "details": "Intimation of Closure of Trading Window",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has declared <strong>100%</strong> dividend, ex-date: 06 Sep 24",
          "dt": "2024-09-06",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has announced <strong>2:5</strong> stock split, ex-date: 08 Jan 25",
          "dt": "2025-01-08",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Jagsonpal Pharmaceuticals Faces Significant Stock Volatility Amid Challenging Market Conditions

2025-03-11 09:35:05

Jagsonpal Pharmaceuticals, a small-cap player in the Pharmaceuticals & Drugs industry, has experienced significant volatility in its stock performance today. The stock opened with a notable loss of 7.28%, reflecting a challenging market environment. Throughout the day, it reached an intraday low of Rs 200.5, marking a decline of 7.28% from the previous close. In terms of performance metrics, Jagsonpal Pharmaceuticals has underperformed its sector by 3.43% today. Over the past two days, the stock has shown a consecutive decline, with a total drop of 6.16%. When compared to the broader market, the stock's one-day performance of -4.28% contrasts with the Sensex's modest decline of 0.53%. Additionally, the stock's one-month performance stands at -6.25%, while the Sensex has decreased by 3.37% during the same period. Analyzing moving averages, the stock is currently positioned higher than its 200-day moving av...

Jagsonpal Pharmaceuticals Shows Strong Rebound Amid Market Volatility in February 2025

2025-02-12 11:45:15

Jagsonpal Pharmaceuticals experienced notable trading activity on February 12, 2025, rebounding after three days of decline. The stock reached an intraday high of Rs 236, showcasing significant volatility. Over the past month, it has outperformed the Sensex, highlighting its resilience in a challenging market environment.

Jagsonpal Pharmaceuticals Faces Significant Intraday Volatility Amid Broader Market Decline

2025-02-11 14:00:15

Jagsonpal Pharmaceuticals has faced notable volatility, with its stock price declining significantly today after an initial gain. The company has underperformed compared to its sector and the broader market over recent days, experiencing consecutive losses. Despite today's downturn, it has shown positive performance over the past month.

Jagsonpal Pharmaceuticals Reports 179.14% Net Profit Growth in Q3 FY24-25

2025-02-10 18:42:44

Jagsonpal Pharmaceuticals has recently experienced a change in evaluation following a strong financial performance in Q3 FY24-25, highlighted by a 179.14% increase in net profit. The company has shown consistent growth over three quarters, with net sales reaching Rs 148.72 crore, up 41.56%.

Jagsonpal Pharmaceuticals Faces Short-Term Challenges Amidst Long-Term Resilience in Market

2025-02-10 10:15:13

Jagsonpal Pharmaceuticals has faced a challenging trading day, with its stock price declining significantly and underperforming its sector. Despite recent losses, the company has shown resilience over the past month, outperforming the Sensex. Technical indicators reveal a mixed performance, with the stock above several moving averages but below the 5-day average.

Jagsonpal Pharmaceuticals Outperforms Market with Strong Stock Performance and Resilience

2025-02-06 15:15:15

Jagsonpal Pharmaceuticals has demonstrated strong market performance, gaining 9.82% on February 6, 2025, significantly outperforming the Sensex. The stock reached an intraday high of Rs 269.75 and has shown a 10.53% increase over the past month, reflecting its competitive position in the pharmaceuticals sector.

Jagsonpal Pharmaceuticals Reports 179% Net Profit Growth in Q3 FY24-25 Amid Market Dynamics

2025-02-04 18:32:51

Jagsonpal Pharmaceuticals has recently adjusted its evaluation, reflecting strong financial performance in Q3 FY24-25, with a significant increase in net profit and sales. The company maintains a low debt-to-equity ratio and has shown consistent positive results over the past three quarters, despite facing some market challenges.

Jagsonpal Pharmaceuticals Shows Resilience Amid Market Fluctuations with Notable Stock Gains

2025-01-30 10:15:14

Jagsonpal Pharmaceuticals has demonstrated notable activity, with a significant stock increase on January 30, 2025. The stock has shown a positive trend over the past three days, outperforming the broader market. Despite some intraday volatility, it remains above several key moving averages, indicating resilience in a fluctuating market.

Jagsonpal Pharmaceuticals Shows Strong Short-Term Performance Amid Market Challenges

2025-01-29 14:30:13

Jagsonpal Pharmaceuticals has seen a notable rise in stock performance, gaining 8.82% on January 29, 2025, and outperforming its sector. The stock has shown a consistent upward trend over two days, accumulating an 11.11% return, while facing challenges with a monthly decline amid broader market fluctuations.

View All News

Announcement

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

08-Apr-2025 | Source : BSE

Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations 2018

Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)

02-Apr-2025 | Source : BSE

Further to our disclosure dated December 16 2023 regarding the receipt of Demand cum Show Cause Notice from the Office of the Principal Commissioner of Customs (the Authority) we wish to submit that the Authority has now passed an order as detailed under Annexure-A. The date of occurrence of event/information is the receipt of order from Office of the Principal Commissioner of Customs i.e. on April 2 2025.